99Tcm-mibi scintimammography in the evaluation of breast lesions and axillary involvement a comparison with mammography and histopathological diagnosis

Nuclear Medicine Communications

Volumn 20, Issue 4, 1999, Pages 317-326

  Arslan, Nuri ^a   OztuRk E ^a   Ilgan, S ^a   Urhan, M ^a   Karagalioglu, O ^a   Bayhan, H ^a   Pekcan, M ^a   Tufan, T ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TRACER;

ADOLESCENT; ADULT; AGED; ARTICLE; AXILLA; BIOPSY; BREAST DISEASE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; MAMMOGRAPHY; METASTASIS; MIDDLE AGED; NEEDLE BIOPSY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; BREAST LESION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SCINTIMAMMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AXILLA; BIOPSY; BIOPSY, NEEDLE; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 0032587810     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-199904000-00007     Document Type: Article

References (25)

1. Robert AS. The epidemiology of breast cancer. In: Daniel BK, Ellen BM, eds. Syllabus: A categorical course in breast imaging. Proceedings of the 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, 1995: 7-20.
2. Kopans DB. The positive predictive value of mammography. AJR 1995; 158: 521-526.
3. Savi A, Gerudini P, Zoli P et al. Biodistribution of Tc-99m methoxyisobutyl-isonitrile (MIBI) in humans. J Nucl Med 1989; 15: 597-600.
4. Khalkhali I, Cutrone JA, Mena IG et al. Scintimammography: The complementary role of Tc-99m-sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
5. Taillefer R, Robidoux A, Lambert R et al. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
6. Meyer JV, Leonard MH, Briscoe E et al. Mammoscinti-graphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37: 926-930.
7. Palmedo H, Schomburg A, Grunwald F et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
8. Khalkhali I, Cutrone J, Mena L Technetium-99m-sesta-mibi scintimammography of breast lesions: Clinical and pathologic follow-up. J Nucl Med 1995; 36: 1784-1789.
9. Delmon-Moingeon I, Piwnica-Worms D, Van den Abbeele AD et al. Uptake of the cation hexakis (2-methoxy isoni-trile) 99Tcm by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2198-2202.
10. Khalkhali I, Cutrone J, Mena L. Technetium-99m-sesta-mibi scintimammography of breast lesions: Clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
11. Khalkhali I, Cutrone J, Mena IG et al. Scintimammography: The complementary role of Tc-99m-sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
12. Palmedo H, Biersack HJ, Lastoria S et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: Results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25: 375-385.
13. Uriarte I, Carril JM, Quirce R et al. Optimization of X-ray mammography and technetium-99m methoxyisobutylisonitrile scintimammography in the diagnosis of non-palpable breast lesions. Eur J Nucl Med 1998; 25: 491-496.
14. Villanueva-Meyer J, Leonard Jr MH, Briscoe E et al. Mam-moscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37: 926-930.
15. Waxman AD. The role of 99mTc-MIBI in imaging breast cancer. Sem Nucl Med 1996; 27: 40-54P.
16. Ivancevic V, Marnitz S, Wandke E et al. Phantom study on the validity of the tumor/background ratio in planar prone scintimammography (abstract). Eur J Nucl Med 1995; 22: 1092P.
17. Palmedo H, Schomburg A, Grunwald F et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
18. Cutrone JA, Yospur LS, Khalkhali I et al. Immunohisto-logical assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions. J Nucl Med 1998; 39: 449-453.
19. Dupont WD, Page DL. Risk factors for breast cancers in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
20. Moretti JL, Caglar M, Cordobés MD et al. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 1995; 22: 97-100.
21. Vecchio SD, Ciarmiello A, Potena MI et al. In vivo detection of multi-drug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
22. Cordobés MD, Starzec A, Moingeon LD et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
23. Danforth DD, Lippman ME. Surgical treatment of breast cancer. In: Diagnosis and management of breast cancer. Philadelphia, PA: W.B. Saunders, 1988: 99-155.
24. Taillefer R, Robidoux A, Turpin S et al. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med 1988; 39: 459-464.
25. Schillaci O, Scopinaro F, Danieli R et al. 90Tcm-sestamibi scintimammography in patients with suspicious breast lesions: Comparison of SPET and planar images in the detection of primary tumours and axillary lymph node involvement. Nucl Med Commun 1997; 18: 839-845.